Cidara Therapeutics — Investor Day (July 2022)
57 slides from Cidara Therapeutics's investor day presentation, Jul 7, 2022

Slide 1: DFCs: a new class of drugs breaking ground in anti-virals and oncology
1 D F C s : a n e w c l a s s o f d r u g s b r e a k i n g g r o u n d i n a n t i - v i r a l s a n d o n c o l o g y J u l y 7 , 2 0 2 2

Slide 2: Forward-looking statements
2 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words “may,” “will,” “estimate,” “plan”, “anticipate,” “expect,” “potential,” “c

Slide 3: Research & Development Day, Thursday, July 7, 2022
Research & Development Day Thursday, July 7, 2022

Slide 4: Rezafungin and Cloudbreak platforms
4 R e z a f u n g i n a n d C l o u d b r e a k p l a t f o r m s REZAFUNGIN CLOUDBREAK • Echinocandin antifungal treatment & prevention • Positive Phase 3 data • Expected PDUFA Q1 2023 • Novel immunotherapy platform: antiviral & oncology • Clinical stage (influenza) • Opportunity to drive future va

Slide 5: Both platforms provide additional ongoing and future value
5 B o t h p l a t f o r m s p r o v i d e a d d i t i o n a l o n g o i n g a n d f u t u r e v a l u e ~$568M P h a s e 2 d a t a ( 2 0 1 9 ) ~$780M P r e c l i n i c a l d a t a ( 2 0 2 1 ) REZAFUNGIN CLOUDBREAK

Slide 6: Both platforms provide additional ongoing and future value
6 B o t h p l a t fo r m s p ro v i d e a d d i t i o n a l o n g o i n g a n d f u t u re va l u e ~$568M P h a s e 2 d a t a ( 2 0 1 9 ) ~$780M P r e c l i n i c a l d a t a ( 2 0 2 1 ) REZAFUNGIN CLOUDBREAK PROGRAM: antifungal RIGHTS: ex-US/Japan • $30M upfront • $9M equity investment • $42M in d

Slide 7: Both platforms provide additional ongoing and future value
7 B o t h p l a t fo r m s p ro v i d e a d d i t i o n a l o n g o i n g a n d f u t u re va l u e ~$568M P h a s e 2 d a t a ( 2 0 1 9 ) ~$780M P r e c l i n i c a l d a t a ( 2 0 2 1 ) REZAFUNGIN CLOUDBREAK PROGRAM: antifungal RIGHTS: ex-US/Japan PROGRAM: influenza DFC RIGHTS: global • $27M upfro

Slide 8: Rezafungin update
8 R e z a f u n g i n u p d a t e REZAFUNGIN • Echinocandin antifungal treatment & prevention • Positive Phase 3 data • Expected PDUFA Q1 2023

Slide 9: Rezafungin update
9 R e z a f u n g i n u p d a t e REZAFUNGIN • Echinocandin antifungal treatment & prevention • Positive Phase 3 data • Expected PDUFA Q1 2023 Rezafungin will be commercialized by third parties in US and Japan • Cidara does not intend to fund commercialization costs • In discussions for US licensing

Slide 10: Cidara's new strategic focus: Cloudbreak program
10 C i d a r a ’ s n e w s t r a t e g i c f o c u s : C l o u d b r e a k D F C p r o g r a m REZAFUNGIN CLOUDBREAK Anti-Fungal Treatment and Prevention Drug Fc Conjugates with broad clinical application

Slide 11: Today's panel members
11 To d ay ’s p a n e l m e m b e rs Ezra Cohen, MD Chief of Hematology-Oncology UCSD Perry Nisen, MD, PhD CEO, Quanta Therapeutics

Slide 12: Today's panel members
12 T o d a y ’ s p a n e l m e m b e r s Ezra Cohen, MD Chief of Hematology-Oncology UCSD Perry Nisen, MD, PhD CEO, Quanta Therapeutics Leslie Tari, PhD Chief Scientific Officer, Cidara

Slide 13: Agenda
13 13 A g e n d a Drug Fc Conjugates what they are (and are not) Les Tari, PhD Advantages of DFCs over conventional modalities in Influenza, SARS and oncology Les Tari, PhD Clinical Potential in oncology Perry Nisen, MD, PhD Ezra Cohen, MD

Slide 14: Cloudbreak creates a new class of drug conjugates: DFCs
14 C LO U D B R E A K ® c re a t e s a n e w c l a s s o f d r u g c o n j u ga t e s : “ D F C s ” Drug Fc Conjugate

Slide 15: Fc moiety is tailored to specific indications
15 F c m o i e t y i s t a i l o r e d t o t o s p e c i f i c i n d i c a t i o n s • IgG1 • Engineered to enhance FcRn binding • Improves half-life compared to wt Fc • Master cell bank established for manufacturing • IgG1 and IgG4 • IgG1 versions mutated to reduce immune effector function • IgG4 l

Slide 16: Different types of targeting moieties attach to the Fc moiety
16 D i f fe re n t t y p e s o f ta rg e t i n g m o i e t i e s ( T M s ) a t ta c h t o t h e Fc m o i e t y SMALL MOLECULES PEPTIDE FUSIONS Fc MOIETY Directed against surface target active sites. Example: Neuraminidase in CD388. Designed to inhibit protein-protein interactions. Example: SARS spik

Slide 17: Targeting moieties are directed against validated targets
17 T a r g e t i n g m o i e t i e s a r e d i r e c t e d a g a i n s t v a l i d a t e d t a r g e t s INFLUENZA: neuraminidase CANCER: adenosine-signaling pathway SARS: spike protein ACE-2 receptor interaction

Slide 18: Potential advantages
18 Po t e n t i a l D F C a d va n ta g e s

Slide 19: DFCs are fundamentally different from ADCs
19 19 D F C s a re f u n d a m e n ta l l y d i f fe re n t f ro m A D C s ADC DFC SM Cytotoxin SM drug conjugate Tumor cell

Slide 20: ADCs employ mAbs directed to cell surface epitopes
20 20 A D C s e m p l o y m A b s d i re c t e d t o c e l l s u r fa c e e p i t o p e s … DFCTumor cell ADC SM drug conjugate

Slide 21: ADCs are internalized by cancer cells to release cytotoxic payloads
21 … a n d a re i n t e r n a l i ze d b y c a n c e r c e l l s t o re l e a s e c y t o t ox i c p ay l o a d s DFCTumor cell ADC SM drug conjugate

Slide 22: DFCs inhibit catalytic activity of surface exposed targets
22 22 DFC SM drug conjugate Tumor cell ADC D F C s i n h i b i t c a t a l y t i c a c t i v i t y o f s u r f a c e e x p o s e d t a r g e t s … CD73 CD73 Tumor cell

Slide 23: DFCs are inherently less toxic than ADCs
23 23 DFC CD73 CD73 SM drug conjugate Tumor cell ADC … a n d a r e i n h e r e n t l y l e s s t o x i c t h a n A D C s Tumor cell

Slide 24: DFCs can accommodate multiple targeting moieties
24 24 D F C s c a n a c c o m m o d a t e m u l t i p l e ta rg e t i n g m o i e t i e s ADC DFC SM Cytotoxin SM drug conjugate

Slide 25: DFCs can accommodate multiple targeting moieties
25 25 D F C s c a n a c c o m m o d a t e m u l t i p l e t a r g e t i n g m o i e t i e s DFC SM drug conjugate Peptide fusion Peptide fusion SM drug conjugate ADC SM Cytotoxin

Slide 26: DFCs have advantages over small molecule therapeutics
26 D F C s h av e a d va n ta g e s o v e r s m a l l m o l e c u l e t h e ra p e u t i c s Potency Distribution to compartments outside plasma (e.g., lung) Oral bioavailability, cell penetration Lipinski’s rules Potentially limited by cell penetration, properties Extra- and intra-cellular compartm

Slide 27: DFCs have advantages over antibodies
27 D F C s h a v e a d v a n t a g e s o v e r a n t i b o d i e s Able to target cryptic sites, small molecule binding pockets Able to modulate drug-Fc-ratio to increase potency Able to install 2 or more discrete targeting moieties Distribution to compartments outside plasma (e.g., lung) Monoclonal

Slide 28: Janssen collaboration on CD388
28 J a n s s e n c o l l a b o r a t i o n o n C D 3 8 8 D F C

Slide 29: Janssen recognized the shortcomings of the flu vaccine and antibodies
29 J a n s s e n re c o g n i ze d t h e s h o r t c o m i n g s o f t h e f l u va c c i n e a n d a n t i b o d i e s Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale and cost Vaccines High Yes AttractiveAttractive No Low

Slide 30: CD388 is in clinical trials for universal influenza prevention
30 C D 3 8 8 i s i n c l i n i c a l t r i a l s f o r u n i v e r s a l i n f l u e n z a p r e v e n t i o n Universal protection: all strains Potential to protect all high risk groups Potential for prevention and treatment Scale and cost High Yes Attractive DFCs Yes CD388 is being developed for u

Slide 31: DFCs designed for universal SARS-2 prevention
31 Peptide fusion D F C s d e s i g n e d f o r ” U n i v e r s a l ” S A R S - 2 p r e v e n t i o n Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale and cost High Yes Attractive DFCs Yes • Peptide engineered to maximize a

Slide 32: Targeting the ACE-spike protein interaction limits viral escape options
32 SARS-2 T a r g e t i n g t h e A C E 2 - s p i k e p r o t e i n i n t e r a c t i o n l i m i t s v i r a l e s c a p e o p t i o n s ACE2 Receptor Fc is being optimized to bind respiratory mucosa for inhaled dosing Peptide is being optimized for stability Peptide has been engineered for compati

Slide 33: Cidara's DFC covers all known SARS-2 variants
33 C i d a r a ’ s S A R S - 2 D F C c o v e r s a l l k n o w n v a r i a n t s mapped on the delta variant spike (PDB code 7WBQ) BA.1 Mutations in CTP-A binding site observed in all omicron sub-lineages observed only in BA.1 Delta variant spike protein CTP-A

Slide 34: Potential for universal coverage of all SARS-2 strains
34 P o t e n t i a l f o r u n i v e r s a l c o v e r a g e o f a l l S A R S - 2 s t r a i n s 0.0 0.50.40.30.20.1 0.130.07 Early Variant D614G/B.1 Delta B.1.617.2 Omicron BA.1/B1.1.529 Omicron/BA.2/B.1/B1.1.529 0.13 0.15 0.21 POTENCYHigher LowermAb1,2 Cidara DFC3 Spike binding IC50 (nM) (ELISA) 1

Slide 35: Potential for universal coverage of all SARS-2 strains
35 P o t e n t i a l f o r u n i v e r s a l c o v e r a g e o f a l l S A R S - 2 s t r a i n s 0.0 Early Variant D614G/B.1 Delta B.1.617.2 Omicron BA.1/B1.1.529 Omicron/BA.2/B.1/B1.1.529 5.04.03.02.01.0 6.00.5 0.15 Spike binding IC50 (nM) (ELISA) mAb1,2 Cidara DFC3 POTENCYHigher Lower 5.93 1. The

Slide 36: Potential for universal coverage of all SARS-2 strains
36 P o t e n t i a l f o r u n i v e r s a l c o v e r a g e o f a l l S A R S - 2 s t r a i n s Early Variant D614G/B.1 Delta B.1.617.2 Omicron BA.1/B1.1.529 Omicron/BA.2/B.1/B1.1.529 0.130.07 0.13 0.15 0.21 0.470.14 0.0 0.50.40.30.20.1 mAb1,2 Cidara DFC3 Spike binding IC50 (nM) (ELISA) POTENCYHigh

Slide 37: Spike-binding data is supported by in vivo efficacy
37 37 S p i k e - b i n d i n g d a t a i s s u p p o r t e d b y i n v i v o e f f i c a c y LOD Lung burden 4 days post-infection Intranasal dosing Omicron BA.1/B1.1.529, in Syrian Hamsters 1mg dose, 6 hrs prior to infection p = 0.0152

Slide 38: SARS-'Flu DFCs could protect against the two major respiratory viruses
38 S A R S - ’ F l u D F C s c o u l d p r o t e c t a g a i n s t t h e t w o m a j o r r e s p i r a t o r y v i r u s e s Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale and cost High Yes Attractive DFCs Yes Flu and SAR

Slide 39: Immune checkpoint pathways
39 I m m u n e c h e c k p o i n t p a t h w ay s

Slide 40: Few patients respond to checkpoint monotherapies
40 40 Fe w e r t h a n 1 5 % o f p a t i e n t s re s p o n d t o c h e c k p o i n t m o n o t h e ra p i e s 1 T-Cell Tumor Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 1. Haslam and Prasad,. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jaman

Slide 41: Few patients respond to checkpoint monotherapies
41 41 F e w e r t h a n 1 5 % o f p a t i e n t s r e s p o n d t o c h e c k p o i n t m o n o t h e r a p i e s 1 Tumor Cell T-Cell Dampens immune response Several inhibitors in development T-Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 1. Hasl

Slide 42: Discussion
42 D i s c u s s i o n

Slide 43: DFCs have the potential to augment PD-1/PD-L1 therapies
43 43 D F C s h a v e t h e p o t e n t i a l t o a u g m e n t P D - 1 / P D - L 1 t h e r a p i e s T-Cell Tumor Cell T-Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 Dampens immune response Several inhibitors in development

Slide 44: DFCs have the potential to augment PD-1/PD-L1 therapies
44 44 D F C s h a v e t h e p o t e n t i a l t o a u g m e n t P D - 1 / P D - L 1 t h e r a p i e s T-Cell Tumor Cell T-Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 CD73 CD73 DFC

Slide 45: DFCs have the potential to augment PD-1/PD-L1 therapies
45 45 D F C s h av e t h e p o t e n t i a l t o a u g m e n t P D - 1 / P D - L 1 t h e ra p i e s PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 T-Cell Tumor Cell T-Cell A2AR A2AR DFC

Slide 46: CD73 DFCs demonstrate robust anti-tumor activity in mouse models
46 46 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle 2. Small molecule AB680 in clinical trials Tumor Volume, Day 121 1. Mouse syngeneic model with a colon tumor cell line (CT26). Scatter plot of individual ani

Slide 47: CD73 DFCs demonstrate robust anti-tumor activity in mouse models
47 47 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle Cidara DFC3 2. Small molecule AB680 in clinical trials 3. Molecule CBO-A Tumor Volume, Day 121 1. Mouse syngeneic model with a colon tumor cell line (CT26).

Slide 48: CD73 DFCs demonstrate robust anti-tumor activity in mouse models
48 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle Cidara DFC3 2. Small molecule AB680 in clinical trials 3. Molecule CBO-A 1. Mouse syngeneic model with a colon tumor cell line (CT26). Scatter plot of individua

Slide 49: CD73 DFCs demonstrate robust anti-tumor activity in mouse models
49 49 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle Cidara DFC3 2. Small molecule AB680 in clinical trials 3. Molecule CBO-A 1. Mouse syngeneic model with a colon tumor cell line (CT26). Scatter plot of indivi

Slide 50: CD73 inhibitors augment PD-1 inhibitor activity
50 50 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 0 21 Tumor cells injected 9 10 15 205 Day 9: ~75 mm3 tumors Day 21: >2000 mm3 tumors

Slide 51: CD73 inhibitors augment PD-1 inhibitor activity
51 51 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 Day 21: >2000 mm3 tumors

Slide 52: CD73 inhibitors augment PD-1 inhibitor activity
52 52 C D 7 3 i n h i b i t o rs a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 Day 21: >2000 mm3 tumors PD-1 mAb

Slide 53: CD73 inhibitors augment PD-1 inhibitor activity
53 53 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 Day 21: >2000 mm3 tumors PD-1 mAb CD73 DFC alone

Slide 54: CD73 inhibitors augment PD-1 inhibitor activity
54 54 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 PD-1 mAb CD73 DFC alone CD73 DFC+ PD-1 mAb

Slide 55: Oncology programs are advancing rapidly
55 O n c o l o g y D F C p r o g r a m s a r e a d v a n c i n g r a p i d l y 2022 2023Q2 Q3 Q4 Q2 Q3 Q4 CD73 CD73 / A2AR PD-1/PD-L1 Combination DFCs will be evaluated and added to the pipeline in 2022 as guided by data SOLID TUMOR PROGRAMS Dis Pre IND Ph1 Dis Pre IND Ph1 Dis Pre IND Ph1 Dis Pre IN

Slide 56: How can Cidara succeed in the crowded space of immuno-oncology?
56 56 H o w c a n C i d a r a s u c c e e d i n t h e c r o w d e d s p a c e o f i m m u n o - o n c o l o g y ? FOCUS: ADENOSINE PATHWAY • Relatively limited competition • Improve outcomes either alone or combined with existing agents • Opportunity to create highly potent and safe “single molecule

Slide 57: Discussion
57 D i s c u s s i o n
Source: SEC EDGAR · 8-K filed Jul 7, 2022
More decks from Cidara Therapeutics Inc
Corporate Update (June 2025)12 slides · Jun 23, 2025
Investor Presentation (May 2024)63 slides · May 3, 2024
Investor Day (September 2023)58 slides · Sep 21, 2023
Technical Presentation (December 2021)24 slides · Dec 14, 2021
Investor Day (September 2021)110 slides · Sep 21, 2021
19th Annual Needham Virtual Healthcare Conference 202038 slides · Apr 14, 2020